RSS   Newsletter   Contact   Advertise with us

Achillion Pharmaceuticals appoints Steven Zelenkofske as executive vice president

Share on Twitter Share on LinkedIn
Staff Writer | New Haven, Conn., USA | August 22, 2018
Steven ZelenkofskeAchillion Pharmaceuticals, a biotechnology company, appoints Steven Zelenkofske to the position of executive vice president and chief medical officer.
Dr. Zelenkofske brings more than 20 years of industry development experience, most recently as Chief Medical Officer of UniQure, a clinical stage gene therapy company, and previously as Chief Medical Officer of Regado Biosciences.

Dr. Zelenkofske has also held leadership positions at Astra-Zeneca, Sanofi-Aventis, Boston Scientific and Novartis.

Dr. Zelenkofske completed his residency training at Philadelphia College of Osteopathic Medicine, followed by fellowships in cardiology and electrophysiology at Graduate Hospital, Philadelphia, and St. Luke’s Hospital, New York, respectively.

He is a graduate of Emory University, where he also earned a Master of Science degree in immunopharmacology. He earned his Doctor of Osteopathy from Philadelphia College of Osteopathic Medicine.

Dr. Zelenkofske is a fellow of the American College of Cardiology, the American College of Chest Physicians, and the American College of Osteopathic Internists.

In addition, Achillion also announced the expansion of its clinical development group with the recent appointments of Laura Barrow to the position of Vice President, Clinical Operations and Head of Project Management, and Marc Uknis to the position of Vice President of Clinical Development, Head of Nephrology Therapeutics.

Dr. Barrow has been in industry over 30 years developing several drugs from the clinic to market.

Dr. Barrow has the breadth and depth of knowledge and experiences in drug development, clinical operations, project management, and compliance in both large pharma and smaller biotech companies including Roche, Bristol-Myers Squibb, Pfizer and Synergy.

Most recently, she worked at Synergy Pharmaceuticals where she progressed a lead program from early phase 2 to a marketed compound.

Dr. Barrow received her Bachelor of Science and Doctor of Pharmacy degrees from St. John’s University, completed the first Rutger’s College of Pharmacy Industrial fellowship in Clinical Pharmacology, and has a certificate in Organizational Effectiveness from Villanova University.

Dr. Uknis was trained in Transplant Surgery at the University of Minnesota and performed hundreds of kidney, liver, pancreas and small intestine transplants as head of programs at Harvard and then University of Massachusetts Medical School where he still holds an adjunct professorship in Molecular Genetics and Microbiology.

Dr. Uknis joined the industry full time more than ten years ago and has held positions of increasing responsibility with ViroPharma, ViroPharma/Shire and CSL Behring.

At each of those companies, he led clinical development programs for complement inhibition in rare diseases, gaining alignment with Regulatory Authorities for multiple accelerated approval developmental programs.

Dr. Uknis also holds a Master’s Degree in Business Administration from George Washington University and is a fellow of the American College of Surgeons.